Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 581 to 590 of 2591 total matches.

An EUA for Casirivimab and Imdevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
1. High-Risk Conditions for COVID-19 Outpatients1 ▶ Age ≥65 years ▶ BMI ≥25 kg/m2 (or, in patients ...
The FDA has issued an Emergency Use Authorization (EUA) for Regeneron's investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV) to be administered together by IV infusion or SC injection for treatment of mild to moderate COVID-19 in adults and pediatric patients (≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):201-2 |  Show IntroductionHide Introduction

An EUA for Baricitinib (Olumiant) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
in combination with the IV antiviral drug remdesivir (Veklury).1 Baricitinib has been available for treatment ...
The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of confirmed or suspected COVID-19 in hospitalized patients ≥2 years old who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO); the EUA requires that baricitinib be used in combination with the IV antiviral drug remdesivir (Veklury). Baricitinib has been available for treatment of rheumatoid arthritis since 2018. Remdesivir was recently approved by the FDA for treatment of COVID-19 in...
Med Lett Drugs Ther. 2020 Dec 28;62(1614):202-3 |  Show IntroductionHide Introduction

Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
is given once daily in 21-day treatment cycles (2 weeks on, 1 week off); one 21-day treatment cycle ...
The oral kinase inhibitor pemigatinib (Pemazyre – Incyte) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Pemigatinib is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):e208-9 |  Show IntroductionHide Introduction

Remdesivir (Veklury) for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
Remdesivir (Veklury) for COVID-19 Table 1. Pharmacology Class Antiviral drug Formulations 100 mg ...
The FDA has approved the antiviral drug remdesivir (Veklury – Gilead) for IV treatment of COVID-19 in hospitalized patients who are ≥12 years old and weigh ≥40 kg. Hospitalized children who are <12 years old or weigh <40 kg can receive remdesivir through an Emergency Use Authorization (EUA). Remdesivir is the first drug to be approved in the US for treatment of COVID-19.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):186-8 |  Show IntroductionHide Introduction

In Brief: New Meningococcal Serogroup B Vaccination Recommendations

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination.1 Booster ...
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):191-2 |  Show IntroductionHide Introduction

An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
to severe disease and/or hospitalization (see Table 1).1 Monoclonal antibodies, such as bamlanivimab ...
The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization (see Table 1).
Med Lett Drugs Ther. 2020 Nov 30;62(1612):185-6 |  Show IntroductionHide Introduction

In Brief: Hydrochlorothiazide and Skin Cancer

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.1 The labeling ...
The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177 |  Show IntroductionHide Introduction

Empagliflozin (Jardiance) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
diabetes.1 To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor ...
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor dapagliflozin (Farxiga) was approved by the FDA for this indication earlier this year.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177-8 |  Show IntroductionHide Introduction

Orphengesic Forte - An Old Analgesic Combination Returns

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
and may be as effective as an opioid/acetaminophen combination for treatment of moderate to severe acute pain.1 MECHANISM ...
A fixed-dose combination of orphenadrine citrate, aspirin, and caffeine (Orphengesic Forte – Galt; previously available as Norgesic Forte) has been approved as a prescription drug by the FDA for treatment of mild to moderate pain caused by acute musculoskeletal disorders. Single-ingredient generic orphenadrine citrate is available by prescription in oral and injectable formulations and has been used for years as an adjunct for treatment of acute musculoskeletal pain. Orphengesic Forte is being marketed as a non-opioid alternative for pain relief.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):180-1 |  Show IntroductionHide Introduction

Comparison Chart: SGLT2 Inhibitors (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
2 (SGLT2) INHIBITORS RENAL DOSAGE ADJUSTMENTS CANAGLIFLOZIN eGFR 30 to ...
View the Comparison Chart: SGLT2 Inhibitors
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8 |  Show IntroductionHide Introduction